Technical Analysis for AZN - Astrazeneca PLC

Grade Last Price % Change Price Change
grade F 36.55 0.72% 0.26
AZN closed up 0.72 percent on Friday, January 18, 2019, on 87 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Earnings due: Feb 1

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical AZN trend table...

Date Alert Name Type % Chg
Jan 18 Oversold Stochastic Weakness 0.00%
Jan 17 Stochastic Buy Signal Bullish 0.72%
Jan 17 Lower Bollinger Band Walk Weakness 0.72%
Jan 17 Oversold Stochastic Weakness 0.72%
Jan 16 Narrow Range Bar Range Contraction 2.12%
Jan 16 NR7 Range Contraction 2.12%
Jan 16 Lower Bollinger Band Walk Weakness 2.12%
Jan 16 Lower Bollinger Band Touch Weakness 2.12%
Jan 16 Oversold Stochastic Weakness 2.12%
Jan 15 Jack-in-the-Box Bearish Bearish Swing Setup 1.22%

Older signals for AZN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for cardiovascular, gastrointestinal, neuroscience, infection, oncology, and respiratory and inflammation diseases worldwide. Its principal products include Atacand for hypertension and heart failure; Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure, and angina; Nexium for acid reflux; Synagis for RSV, a respiratory infection in infants; Seroquel IR for schizophrenia and bipolar disorders; and Seroquel XR for schizophrenia, bipolar disorder, and major depressive disorders. The company principal products also comprise Zoladex for prostate and breast cancer; Pulmicort for asthma and chronic obstructive pulmonary diseases; and Symbicort for asthma and chronic obstructive pulmonary diseases. In addition, it has 84 pipeline projects, which include 71 projects in various clinical phases of development. The company markets its products to primary care and specialist doctors through distributors or local representative offices. AstraZeneca PLC has collaboration agreements with Amgen, Inc. to develop and commercialize monoclonal antibodies; Ironwood Pharmaceuticals, Inc to co-develop and co-commercialize linaclotide in China; BIND Therapeutics, Inc. to develop and commercialize cancer nanomedicine; and WuXi AppTec to develop and commercialize MEDI5117, a biologic for autoimmune and inflammatory diseases. It also has a strategic alliance with Isis Pharmaceuticals, Inc. for the discovery and development of novel generation antisense therapeutics; and a strategic collaboration with FibroGen, Inc. to develop and commercialize FG-4592, a compound for the treatment of anemia associated with chronic kidney disease and end-stage renal disease. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.
Is AZN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 41.78
52 Week Low 32.69
Average Volume 5,029,738
200-Day Moving Average 37.6244
50-Day Moving Average 38.8152
20-Day Moving Average 37.4295
10-Day Moving Average 37.021
Average True Range 0.7763
ADX 23.12
+DI 20.4987
-DI 33.41
Chandelier Exit (Long, 3 ATRs ) 37.0511
Chandelier Exit (Short, 3 ATRs ) 37.7539
Upper Bollinger Band 39.3577
Lower Bollinger Band 35.5013
Percent B (%b) 0.27
BandWidth 10.303103
MACD Line -0.6623
MACD Signal Line -0.5258
MACD Histogram -0.1365
Fundamentals Value
Market Cap 92.55 Billion
Num Shares 2.53 Billion
EPS 1.52
Price-to-Earnings (P/E) Ratio 24.05
Price-to-Sales 3.91
Price-to-Book 6.22
PEG Ratio 2.37
Dividend 0.90
Dividend Yield 2.46%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 37.33
Resistance 3 (R3) 37.34 37.09 37.20
Resistance 2 (R2) 37.09 36.89 37.09 37.16
Resistance 1 (R1) 36.82 36.77 36.70 36.81 37.11
Pivot Point 36.57 36.57 36.51 36.57 36.57
Support 1 (S1) 36.30 36.37 36.18 36.29 35.99
Support 2 (S2) 36.05 36.25 36.05 35.94
Support 3 (S3) 35.78 36.05 35.90
Support 4 (S4) 35.77